Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

Condition:   Persistent Allergic Asthma
Interventions:   Drug: Omalizumab;   Drug: Placebo
Sponsors:   Novartis;   Genentech
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.